These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9337063)

  • 1. A laboratory comparison of T cell depletion by CD34+ cell immunoaffinity selection and in vitro Campath-1M treatment: clinical implications for bone marrow transplantation and donor leukocyte therapy.
    Clarke E; Potter MN; Oakhill A; Cornish JM; Steward CG; Pamphilon DH
    Bone Marrow Transplant; 1997 Oct; 20(7):599-605. PubMed ID: 9337063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
    Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries.
    Clarke E; Potter MN; Hale G; Waldmann H; Lankester A; Cornish JM; Steward CG; Marks DI; Oakhill A; Pamphilon DH
    Bone Marrow Transplant; 1998 Jul; 22(2):117-24. PubMed ID: 9707017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T cell depletion strategies using different CD34+ selection systems or CAMPATH-1.
    Dreger P; Viehmann K; Steinmann J; Eckstein V; Müller-Ruchholtz W; Löffler H; Schmitz N
    Exp Hematol; 1995 Feb; 23(2):147-54. PubMed ID: 7530212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse.
    Naparstek E; Or R; Nagler A; Cividalli G; Engelhard D; Aker M; Gimon Z; Manny N; Sacks T; Tochner Z
    Br J Haematol; 1995 Mar; 89(3):506-15. PubMed ID: 7734348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of CAMPATH-1H in BMT patients.
    Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
    Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell depletion of allogeneic bone marrow grafts: enrichment of mononuclear cells using the COBE Spectra cell processor, followed by immunoselection of CD34(+) cells.
    Olivero S; Novakovitch G; Ladaique P; Sainty D; Viret F; Faucher C; Stoppa AM; Blaise D; Chabannon C
    Cytotherapy; 1999; 1(6):469-77. PubMed ID: 20443236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison between bone marrow and G-CSF-mobilized peripheral blood allografts undergoing clinical scale CD34+ cell selection.
    Hassan HT; Zeller W; Stockschläder M; Krüger W; Hoffknecht MM; Zander AR
    Stem Cells; 1996 Jul; 14(4):419-29. PubMed ID: 8843543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
    Hale G; Waldmann H
    Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of bone marrow T lymphocytes treated with CAMPATH 1G on megakaryocyte colony formation.
    Deutsch VR; Nagler A; Slavin S; Condiotti R; Levine RF; Eldor A
    Exp Hematol; 1993 Oct; 21(11):1427-35. PubMed ID: 8405223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro T cell depletion using Campath 1M for mismatched BMT for severe combined immunodeficiency (SCID).
    Dickinson AM; Reid MM; Abinun M; Peak J; Brigham K; Dunn J; Cant AJ
    Bone Marrow Transplant; 1997 Feb; 19(4):323-9. PubMed ID: 9051241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of T cell depletion with Campath-1M on immune reconstitution after chemotherapy and allogeneic bone marrow transplant as treatment for leukaemia.
    Lowdell MW; Craston R; Ray N; Koh M; Galatowicz G; Prentice HG
    Bone Marrow Transplant; 1998 Apr; 21(7):679-86. PubMed ID: 9578307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
    Naparstek E; Delukina M; Or R; Nagler A; Kapelushnik J; Varadi G; Strauss N; Cividalli G; Aker M; Brautbar C; Waldmann H; Hale G; Slavin S
    Exp Hematol; 1999 Jul; 27(7):1210-8. PubMed ID: 10390197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?
    Simpson D
    BioDrugs; 2003; 17(3):147-54. PubMed ID: 12749751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
    Novitzky N; Thomas V; du Toit C
    Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
    Ratzinger G; Reagan JL; Heller G; Busam KJ; Young JW
    Blood; 2003 Feb; 101(4):1422-9. PubMed ID: 12393688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells.
    Hederer RA; Guntermann C; Miller N; Nagy P; Szollosi J; Damjanovich S; Hale G; Alexander DR
    Int Immunol; 2000 Apr; 12(4):505-16. PubMed ID: 10744652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CAMPATH-1M T-cell depleted BMT for SCID: long-term follow-up of 19 children treated 1987-98 in a single center.
    Gennery AR; Dickinson AM; Brigham K; Barge D; Spickett GP; Curtis A; Spencer V; Jackson A; Cavanagh G; Carter V; Palmer P; Flood TJ; Cant AJ; Abinun M
    Cytotherapy; 2001; 3(3):221-32. PubMed ID: 12171729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD34 selection using three immunoselection devices: comparison of T-cell depleted allografts.
    O'Donnell PV; Myers B; Edwards J; Loper K; Rhubart P; Noga SJ
    Cytotherapy; 2001; 3(6):483-8. PubMed ID: 11953032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of anti-CD52 antibody alemtuzumab on ex-vivo culture of umbilical cord blood stem cells.
    Lim CK; Sun L; Feng Q; Law P; Chua WT; Lim SN; Hwang WY
    J Hematol Oncol; 2008 Oct; 1():19. PubMed ID: 18947412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.